BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Strijker M, Chen JW, Mungroop TH, Jamieson NB, van Eijck CH, Steyerberg EW, Wilmink JW, Groot Koerkamp B, van Laarhoven HW, Besselink MG. Systematic review of clinical prediction models for survival after surgery for resectable pancreatic cancer. Br J Surg 2019;106:342-54. [PMID: 30758855 DOI: 10.1002/bjs.11111] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
Number Citing Articles
1 Deforth M, Gebhard CE, Bengs S, Buehler PK, Schuepbach RA, Zinkernagel AS, Brugger SD, Acevedo CT, Patriki D, Wiggli B, Twerenbold R, Kuster GM, Pargger H, Schefold JC, Spinetti T, Wendel-garcia PD, Hofmaenner DA, Gysi B, Siegemund M, Heinze G, Regitz-zagrosek V, Gebhard C, Held U. Development and validation of a prognostic model for the early identification of COVID-19 patients at risk of developing common long COVID symptoms. Diagn Progn Res 2022;6:22. [DOI: 10.1186/s41512-022-00135-9] [Reference Citation Analysis]
2 Zhou HF, Wang JL, Yang W, Zhou C, Shen Y, Wu LL, Pei ZL, Zhou WZ, Liu S, Shi HB. Survival prediction for patients with malignant biliary obstruction caused by pancreatic cancer undergoing biliary drainage: the COMBO-PaS model. Surg Endosc 2022. [PMID: 36261643 DOI: 10.1007/s00464-022-09698-6] [Reference Citation Analysis]
3 Cucchetti A, Crippa S, Dajti E, Binda C, Fabbri C, Falconi M, Ercolani G. Trial sequential analysis of randomized controlled trials on neoadjuvant therapy for resectable pancreatic cancer. European Journal of Surgical Oncology 2022. [DOI: 10.1016/j.ejso.2022.04.011] [Reference Citation Analysis]
4 Li D, Wang L, Cai W, Liang M, Ma X, Zhao X. Prognostic stratification in patients with pancreatic ductal adenocarcinoma after curative resection based on preoperative pancreatic contrast-enhanced CT findings. European Journal of Radiology 2022. [DOI: 10.1016/j.ejrad.2022.110313] [Reference Citation Analysis]
5 Linder S, Holmberg M, Engstrand J, Ghorbani P, Sparrelid E. Prognostic impact of para-aortic lymph node status in resected pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous neoplasm – Time to consider a reclassification? Surgical Oncology 2022. [DOI: 10.1016/j.suronc.2022.101735] [Reference Citation Analysis]
6 Mir ZM, Golding H, McKeown S, Nanji S, Flemming JA, Groome PA. Appraisal of multivariable prognostic models for post-operative liver decompensation following partial hepatectomy: a systematic review. HPB (Oxford) 2021;23:1773-88. [PMID: 34332894 DOI: 10.1016/j.hpb.2021.06.430] [Reference Citation Analysis]
7 Quero G, Pecorelli N, Paiella S, Fiorillo C, Petrone MC, Rosa F, Capretti G, Laterza V, Kauffmann E, Nobile S, Butturini G, Ferrari G, Coratti A, Casadei R, Mazzaferro V, Boggi U, Zerbi A, Salvia R, Falconi M, Alfieri S. Quantitative assessment of the impact of COVID-19 pandemic on pancreatic surgery: an Italian multicenter analysis of 1423 cases from 10 tertiary referral centers. Updates Surg 2021. [PMID: 34817837 DOI: 10.1007/s13304-021-01171-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
8 Palumbo D, Mori M, Prato F, Crippa S, Belfiori G, Reni M, Mushtaq J, Aleotti F, Guazzarotti G, Cao R, Steidler S, Tamburrino D, Spezi E, Del Vecchio A, Cascinu S, Falconi M, Fiorino C, De Cobelli F. Prediction of Early Distant Recurrence in Upfront Resectable Pancreatic Adenocarcinoma: A Multidisciplinary, Machine Learning-Based Approach. Cancers (Basel) 2021;13:4938. [PMID: 34638421 DOI: 10.3390/cancers13194938] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
9 Dang C, Wang M, Zhu F, Qin T, Qin R. Controlling nutritional status (CONUT) score-based nomogram to predict overall survival of patients with pancreatic cancer undergoing radical surgery. Asian J Surg 2021:S1015-9584(21)00513-3. [PMID: 34493426 DOI: 10.1016/j.asjsur.2021.08.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
10 Dhiman P, Ma J, Navarro CA, Speich B, Bullock G, Damen JA, Kirtley S, Hooft L, Riley RD, Van Calster B, Moons KGM, Collins GS. Reporting of prognostic clinical prediction models based on machine learning methods in oncology needs to be improved. J Clin Epidemiol 2021;138:60-72. [PMID: 34214626 DOI: 10.1016/j.jclinepi.2021.06.024] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
11 Muttillo EM, Ciardi A, Saullo P, Troiano R, Masselli G, Guida M, Tortora A, Sperduti I, Marinello G, Chirletti P, Caronna R. A Prognostic Score for Predicting Survival in Patients With Pancreatic Head Adenocarcinoma and Distal Cholangiocarcinoma. In Vivo 2021;35:507-15. [PMID: 33402503 DOI: 10.21873/invivo.12285] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Hirono S, Kawai M, Okada KI, Miyazawa M, Kitahata Y, Kobayashi R, Hayami S, Ueno M, Yamaue H. Complete circumferential lymphadenectomy around the superior mesenteric artery with preservation of nerve plexus reduces locoregional recurrence after pancreatoduodenectomy for resectable pancreatic ductal adenocarcinoma. Eur J Surg Oncol 2021:S0748-7983(21)00567-9. [PMID: 34127329 DOI: 10.1016/j.ejso.2021.06.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
13 Dreyer SB, Jamieson NB, Chang DK, Biankin AV. Molecular Subtyping of Pancreatic Cancer. Textbook of Pancreatic Cancer 2021. [DOI: 10.1007/978-3-030-53786-9_21] [Reference Citation Analysis]
14 Groot VP, Daamen LA, He J, Wolfgang CL, Molenaar IQ. Patterns of Recurrence After Surgery for Pancreatic Cancer. Textbook of Pancreatic Cancer 2021. [DOI: 10.1007/978-3-030-53786-9_74] [Reference Citation Analysis]
15 van Wijk L, de Klein GW, Kanters MA, Patijn GA, Klaase JM. The ultimate preoperative C-reactive protein-to-albumin ratio is a prognostic factor for survival after pancreatic cancer resection. Eur J Med Res 2020;25:46. [PMID: 33028394 DOI: 10.1186/s40001-020-00444-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Ren H, Wu CR, Qiu GT, Zhang LP, Aimaiti S, Wang CF. Equipping the American Joint Committee on Cancer Staging for Resectable Pancreatic Ductal Adenocarcinoma with Tumor Grade: A Novel Staging System. J Oncol 2020;2020:9093729. [PMID: 33014058 DOI: 10.1155/2020/9093729] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
17 Blomstrand H, Green H, Fredrikson M, Gränsmark E, Björnsson B, Elander NO. Clinical characteristics and blood/serum bound prognostic biomarkers in advanced pancreatic cancer treated with gemcitabine and nab-paclitaxel. BMC Cancer 2020;20:950. [PMID: 33008332 DOI: 10.1186/s12885-020-07426-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
18 Kim DW, Lee SS, Kim SO, Kim JH, Kim HJ, Byun JH, Yoo C, Kim KP, Song KB, Kim SC. Estimating Recurrence after Upfront Surgery in Patients with Resectable Pancreatic Ductal Adenocarcinoma by Using Pancreatic CT: Development and Validation of a Risk Score. Radiology 2020;296:541-51. [PMID: 32662759 DOI: 10.1148/radiol.2020200281] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
19 Moekotte AL, van Roessel S, Malleo G, Rajak R, Ecker BL, Fontana M, Han HS, Rabie M, Roberts KJ, Khalil K, White SA, Robinson S, Halimi A, Zarantonello L, Fusai GK, Gradinariu G, Alseidi A, Bonds M, Dreyer S, Jamieson NB, Mowbray N, Al-Sarireh B, Mavroeidis VK, Soonawalla Z, Napoli N, Boggi U, Kent TS, Fisher WE, Tang CN, Bolm L, House MG, Dillhoff ME, Behrman SW, Nakamura M, Ball CG, Berger AC, Christein JD, Zureikat AH, Salem RR, Vollmer CM, Salvia R, Besselink MG, Abu Hilal M, Aljarrah R, Barrows C, Cagigas MN, Lai ECH, Wellner U, Aversa J, Dickson PV, Ohtsuka T, Dixon E, Zheng R, Kowalski S, Freedman-Weiss M; International Study Group on Ampullary Cancer (ISGACA) Collaborators. Development and external validation of a prediction model for survival in patients with resected ampullary adenocarcinoma. Eur J Surg Oncol 2020;46:1717-26. [PMID: 32624291 DOI: 10.1016/j.ejso.2020.04.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
20 Latenstein AEJ, van Roessel S, van der Geest LGM, Bonsing BA, Dejong CHC, Groot Koerkamp B, de Hingh IHJT, Homs MYV, Klaase JM, Lemmens V, Molenaar IQ, Steyerberg EW, Stommel MWJ, Busch OR, van Eijck CHJ, van Laarhoven HWM, Wilmink JW, Besselink MG; Dutch Pancreatic Cancer Group. Conditional Survival After Resection for Pancreatic Cancer: A Population-Based Study and Prediction Model. Ann Surg Oncol 2020;27:2516-24. [PMID: 32052299 DOI: 10.1245/s10434-020-08235-w] [Cited by in Crossref: 14] [Cited by in F6Publishing: 20] [Article Influence: 4.7] [Reference Citation Analysis]
21 van Roessel S, Strijker M, Steyerberg EW, Groen JV, Mieog JS, Groot VP, He J, De Pastena M, Marchegiani G, Bassi C, Suhool A, Jang JY, Busch OR, Halimi A, Zarantonello L, Groot Koerkamp B, Samra JS, Mittal A, Gill AJ, Bolm L, van Eijck CH, Abu Hilal M, Del Chiaro M, Keck T, Alseidi A, Wolfgang CL, Malleo G, Besselink MG. International validation and update of the Amsterdam model for prediction of survival after pancreatoduodenectomy for pancreatic cancer. Eur J Surg Oncol 2020;46:796-803. [PMID: 31924432 DOI: 10.1016/j.ejso.2019.12.023] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
22 Nakagawa N, Yamada S, Sonohara F, Takami H, Hayashi M, Kanda M, Kobayashi D, Tanaka C, Nakayama G, Koike M, Fujiwara M, Kodera Y. Clinical Implications of Naples Prognostic Score in Patients with Resected Pancreatic Cancer. Ann Surg Oncol 2020;27:887-95. [PMID: 31848811 DOI: 10.1245/s10434-019-08047-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 5.3] [Reference Citation Analysis]
23 Mu W, Wang Z, Zöller M. Ping-Pong-Tumor and Host in Pancreatic Cancer Progression. Front Oncol 2019;9:1359. [PMID: 31921628 DOI: 10.3389/fonc.2019.01359] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
24 Zhou YY, Chen LP, Zhang Y, Hu SK, Dong ZJ, Wu M, Chen QX, Zhuang ZZ, Du XJ. Integrated transcriptomic analysis reveals hub genes involved in diagnosis and prognosis of pancreatic cancer. Mol Med 2019;25:47. [PMID: 31706267 DOI: 10.1186/s10020-019-0113-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
25 Feng SS, Li HB, Fan F, Li J, Cao H, Xia ZW, Yang K, Zhu XS, Cheng TT, Cheng Q. Clinical characteristics and disease-specific prognostic nomogram for primary gliosarcoma: a SEER population-based analysis. Sci Rep 2019;9:10744. [PMID: 31341246 DOI: 10.1038/s41598-019-47211-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
26 Permuth JB, Clark Daly A, Jeong D, Choi JW, Cameron ME, Chen DT, Teer JK, Barnett TE, Li J, Powers BD, Kumar NB, George TJ, Ali KN, Huynh T, Vyas S, Gwede CK, Simmons VN, Hodul PJ, Carballido EM, Judge AR, Fleming JB, Merchant N, Trevino JG. Racial and ethnic disparities in a state-wide registry of patients with pancreatic cancer and an exploratory investigation of cancer cachexia as a contributor to observed inequities. Cancer Med 2019;8:3314-24. [PMID: 31074202 DOI: 10.1002/cam4.2180] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]